Arbutus Biopharma Corporation Культура компании

Dr. Michael J. Sofia, also known as Mike, Ph.D. has been the Chief Scientific Officer of Arbutus Biopharma Corporation since 2015. Dr. Sofia co-founded Arbutus Biopharma Inc. in 2012 and serves as its Chief Scientific Officer and Head of R&D since July 2014. He served as President of OnCore Biopharma. He served as Vice President of Chemistry at Gilead Pharmasset LLC (Pharmasset, Inc) from August 2005 to January 2012. He served as Senior Vice President of Chemistry, Princeton Site Head and Senior Advisor at Gilead Sciences from January 2012 to December 2012. He joined Pharmasset in 2005 and had responsibility for research strategy, medicinal chemistry, process research, computational chemistry and analytical chemistry functions and was a clinical development project leader. Prior to Pharmasset, he was Group Director, New Leads Chemistry at Bristol-Myers Squibb from 1999 to 2005, Vice President of Research at Intercardia Research Labs (formerly Transcell Technologies) and was Research Investigator and Project Leader at Lilly Research Labs, Eli Lilly & Co. From 1993 to 1999, Dr. Sofia established and directed the research programs at Transcell Technologies, first as Director of Chemistry and then as Vice-President of Research. He has over 18 years of drug discovery and 11 years of research management experience at Bristol-Myers Squibb, Transcell Technologies and Eli Lilly. At Bristol-Myers Squibb, he lead high throughput chemistry capabilities that supported drug discovery efforts across six therapeutic areas, including virology, cardiovascular, metabolic diseases, oncology, inflammatory diseases and neuroscience. From 1993-1999, Dr. Sofia established and directed the chemical research programs at Transcell Technologies, which focused on the discovery of novel antibacterial agents. At Eli Lilly, he developed anti-inflammatory agents for the treatment of asthma, inflammatory bowel disease and psoriasis. Since March 2013, he has been an adjunct professor at the Drexel University School of Medicine. He served as a member of its board of directors of OnCore Biopharma from May 2012 to August 2014. He has authored 100 publications, 9 book chapters and numerous abstracts and is an inventor on over 30 patents. He also holds a professorship position at the Baruch S. Blumberg Institute and is on the editorial board of several scientific journals. He is the recipient of the PA BIO 2014 Scientific Achievement Award for the discovery of Sofosbuvir. He did his postdoctoral training in synthetic organic chemistry, as an NIH fellow, at Columbia University. Dr. Sofia earned his Ph.D. in Organic Chemistry from the University of Illinois at Urbana-Champaign and his B.A. in Chemistry from Cornell University.

Dr. Elizabeth Howard, also known as Liz, Ph.D., J.D. has been an Executive Vice President and General Counsel of Arbutus Biopharma Corporation since March 8, 2016. Dr. Howard joined Arbutus from Orrick, where she was an Intellectual Property Partner and Co-chaired Orrick's life sciences practice. Dr. Howard focused on patent infringement litigation, with an emphasis on the life sciences. Dr. Howard holds a B.A. with honors from the University of California, Santa Barbara, a Ph.D. in Molecular Biology from the University of California, Berkeley and a J.D. from the University of California, Hastings College of the Law.

Dr. Peter Lutwyche, Ph.D., has been Chief Technology Officer at Arbutus Biopharma Corporation since July 31, 2015 and served as its Senior Vice President of Pharmaceutical Development from May 2008 to July 30, 2015. Dr. Lutwyche served as Vice President of Pharmaceutical Development at Tekmira Pharmaceuticals Corp., since September 29, 2008. Dr. Lutwyche joined Protiva Biotherapeutics Inc. in February 2008 where he served as Vice President of Pharmaceutical Development. Dr. Lutwyche joined Tekmira from QLT Inc., where he served for ten years. He served as Director of Pharmaceutical Development of QLT Inc. until 2007. During his tenure at QLT, Dr. Lutwyche contributed to the development and commercialization of Visudyne as well as leading manufacturing and chemistry efforts for numerous preclinical and clinical stage products. Prior to QLT, he served as a research scientist of Inex Pharmaceuticals Corporation working with lipid-based formulations of nucleic acids and antibiotics. Dr. Lutwyche holds a Ph.D. in Chemistry from the University of British Columbia.

Dr. William T. Symonds III, also known as Bill, PharmD, has been the Chief Development Officer of Arbutus Biopharma Corporation (formerly Tekmira Pharmaceuticals Corporation) since 2015. Dr. Symonds has been Senior Vice President of Clinical Research at Roivant Sciences, Inc., since May 2014. Prior to that, he served as Vice-President of Liver Disease Therapeutic Area at Gilead Sciences, Inc. from February 2012 to April 2014. He served as Senior Vice President at Pharmasset, Inc. He served as a Vice President of Clinical Pharmacology of Gilead Pharmasset LLC from January 24, 2007 to January 2012. He served as Senior Advisor of OnCore since November 2014. From 1993 to 2007, he held various positions of increasing responsibility at GlaxoSmithKline, most recently as Director, Antiviral Clinical Pharmacology and Discovery Medicine. He Led the development of compounds for hepatitis B virus and hepatitis C virus infection, most notably Sovaldi?? for hepatitis C and Contributed to new drug approvals for Ziagen??, Agenerase??, and Epzicom?? during his 15-year tenure at GlaxoSmithKline. He is a seasoned drug development professional with extensive experience in the clinical development of multiple new drug candidates from phase 1 to phase 4. He has been an Executive Director of Arbutus Biopharma Corporation since March 4, 2015. He served as a Director of OnCore Biopharma, Inc. since August 2014. Dr. Symonds received his Doctorate of Pharmacy from Campbell University in North Carolina and he completed a Fellowship in Clinical Pharmacokinetics focusing on anti-infective pharmacology at the Clinical Pharmacokinetics Laboratory at Millard Fillmore Hospital in Buffalo, New York.

Wendy Aspden-Curran serves as the Vice President Clinical Operations of Arbutus Biopharma Corporation. Wendy started at Arbutus Biopharma Corporation in Jul of 2016. Wendy currently resides in the Greater New York City Area.

Bruce Dorsey serves as the Vice President, Chemistry of Arbutus Biopharma Corporation. Bruce started at Arbutus Biopharma Corporation in Jan of 2015. Bruce currently resides in the Greater Philadelphia Area.

Patricia Mendez serves as the Vice President Clinical Development of Arbutus Biopharma Corporation. Patricia started at Arbutus Biopharma Corporation in Feb of 2017. Patricia currently resides in the Greater New York City Area.

Gaston Picchio serves as the Chief Development Officer of Arbutus Biopharma Corporation. Gaston started at Arbutus Biopharma Corporation in Oct of 2018. Gaston currently resides in the Greater Philadelphia Area.

Michael Child serves as the Vice President Clinical Operations of Arbutus Biopharma Corporation. Michael started at Arbutus Biopharma Corporation in December of 2018. Michael currently resides in the Greater Philadelphia Area.